drug_type
RELEVANT_DRUG
intervention_type
Drug (monoclonal antibody)
drug_description
Humanized IgG1 anti-CD20 monoclonal antibody that selectively depletes CD20+ B cells via ADCC, CDC, and apoptosis, reducing B‑cell antigen presentation, proinflammatory cytokines, and autoantibody production to dampen B–T cell interactions and CNS inflammation in MS. Also known as RO4964913.
nci_thesaurus_concept_id
C66250
nci_thesaurus_definition
A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.
drug_mesh_term
ocrelizumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20+ B cells via ADCC, complement-dependent cytotoxicity, and apoptosis; reduces B-cell antigen presentation, cytokine and autoantibody production, dampening B–T cell interactions and neuroinflammation.
drug_name
Ocrelizumab
nct_id_drug_ref
NCT06675955